Product Profiles: Alzheimer's Disease - Immunotherapies can revolutionize treatment paradigm
Datamonitor, November 2011, Pages: 150
The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration.
Features and benefits
- Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating Alzheimer’s disease.
- Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Understand how marketed brands are positioned in the Alzheimer’s disease treatment algorithm.
- Determine to what extent future therapies satisfy the main clinical unmet needs in Alzheimer’s disease treatment.
Highlights
- Datamonitor’s physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mild cognitive impairment to severe Alzheimer’s disease. However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US, marketed competition heightens in Japan, and European patents near expiry.
- Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer’s disease treatment and become future market leaders. However, each program carries a caveat. J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly is betting on solanezumab’s Phase II biomarker effect translating into tangible benefits.
- A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihood of navigating through clinical trials. Late-stage symptomatic drugs include Eisai’s Aricept patch and GSK’s 5-HT6 receptor agonist SB-742457, although the potential rewards on offer for these candidates are lower than for the immunotherapies.
Your key questions answered
- How do drugs in development compare to the current gold-standard treatment for Alzheimer’s disease?
- Which are the most likely drugs to emerge from the pipeline and how will they impact the way Alzheimer’s disease is treated?
- How are marketed brands positioned in the Alzheimer’s disease treatment algorithm?
- What are the comparative strengths and weaknesses of the key Alzheimer’s disease brands and pipeline candidates?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
PRODUCT OVERVIEW
Product Overview
MARKETED PRODUCT PROFILES
Aricept (donepezil; Eisai/Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Exelon (rivastigmine; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Razadyne (galantamine; Johnson & Johnson/Shire)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Namenda (memantine; Forest/Merz/Lundbeck)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
Bapineuzumab (Johnson & Johnson/Pfizer)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Solanezumab (LY2062430; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Gammagard (intravenous immunoglobulin; Baxter)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Aricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
SB-742457 (GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other key disease-modifying drugs in development for Alzheimer’s disease
ACC-001 (conjugate beta-amyloid vaccine; Johnson & Johnson/Pfizer)
AD02 (beta-amyloid vaccine; GlaxoSmithKline/Affiris)
Avagacestat (BMS-708163; Bristol-Myers Squibb)
CAD106 (beta-amyloid vaccine; Novartis/Cytos Biotechnology)
CERE-110 (AAV2-NGF; Ceregene)
CHF5074 (Chiesi Pharmaceuticals)
Crenezumab (R7412/MABT5102A; Roche/AC Immune)
Davunetide (AL-108; Allon Therapeutics)
ELND005 (scyllo-inositol; Elan)
EHT 0202 (etazolate; ExonHit Therapeutics)
Gantenerumab (R1450; Roche/MorphoSys)
Masitinib (AB1010; AB Science)
NIC5-15 (Humanetics)
Nypta (tideglusib; Noscira)
Octagam (intravenous immunoglobulin; Octapharma)
PF-04494700 (Pfizer/TransTech Pharma)
PBT2 (Prana Biotechnology)
Rember (methylthioninium chloride; TauRx Pharmaceuticals)
T-817MA (Toyama Chemical)
Other key symptomatic drugs in development for Alzheimer’s disease
ABT-288 (Abbott Laboratories)
Dimebon (latrepirdine; Pfizer/Medivation)
EVP-6124 (EnVivo Pharmaceuticals)
GSK239512 (GlaxoSmithKline)
Ispronicline (AZD3480; AstraZeneca/Targacept)
Lu AE58054 (Lundbeck)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX A – SURVEY INFORMATION
Physician research methodology
Physician sample breakdown
The survey questionnaire
Screener
Section 10: Alzheimer’s disease regimens
Section 11: Treated disease stages
Section 12: Treatment flow – mild cognitive impairment due to Alzheimer’s disease
Section 13: Treatment flow – mild Alzheimer’s disease
Section 14: Treatment flow – moderate Alzheimer’s disease
Section 15: Treatment flow – severe Alzheimer’s disease
APPENDIX B
PharmaVitae Explorer database
Datamonitor drug assessment scorecard
Contributing experts
Conferences attended
Report methodology
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
